Glycemic variability: Both sides of the story

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Ceriello, Antonio ^a   Kilpatrick, Eric S ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERGLYCEMIA; PROGNOSIS; RISK FACTORS;

EID: 84891780161     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2030     Document Type: Article

References (32)

1. Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Re-habil 2010;17(Suppl. 1):S15-S19
2. Ceriello A, Ihnat MA. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Dia-bet Med 2010;27:862-867
3. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
4. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011;34: 2237-2243
5. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486-1490
6. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008;51:365-371
7. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-2202
8. Monnier L, Colette C, Leiter L, et al.; PGR Group. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007;30: 185-186; author reply 187-188
9. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycae-mic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008;34:612-616
10. Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995;38:672-679
11. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997;96: 1750-1754
12. Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med 2012;125:416.e9-e18
13. Schisano B, Tripathi G, McGee K, McTernan PG, Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Dia-betologia 2011;54:1219-1226
14. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072
15. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
16. Marfella R, Barbieri M, Ruggiero R, et al. Bariatric surgery reduces oxidative stress by blunting 24-h acute glucose fluctuations in type 2 diabetic obese patients. Diabetes Care 2010;33:287-289
17. Di Flaviani A, Picconi F, Di Stefano P, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 2011;34:1605-1609
18. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354
19. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082
20. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 17 January 2013 [Epub ahead of print]
21. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Dia-betologia 2001;44:1215-1220
22. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Dia-betologia 2009;52:2229-2232
23. Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009;32:1901-1903
24. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818
25. Kilpatrick ES. The rise and fall of HbA(1c) as a risk marker for diabetes complications. Diabetologia 2012;55:2089-2091
26. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386
27. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myo-cardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34: 855-857
28. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51:183-190
29. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Tech 2011; 5:86-92
30. Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Dia-betologia 2010;53:562-571
31. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
32. Wakil A, Smith KA, Atkin SL, Kilpatrick ES. Short-term glucose variability in healthy volunteers is not associated with raised oxidative stress markers. Diabetes Obes Metab 2012;14:1047-1049